Advertisement

Topics

EMA approval for biosimilar insulin glargine Semglee

06:26 EST 15 Feb 2018 | Generics and Biosimilars Initiative

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 25 January 2018 that it had recommended granting marketing authorization for the insulin glargine biosimilar Semglee.

Original Article: EMA approval for biosimilar insulin glargine Semglee

NEXT ARTICLE

More From BioPortfolio on "EMA approval for biosimilar insulin glargine Semglee"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...